Preclinical Ischemic Stroke Research Services
An ischemic stroke occurs when blood vessels supplying the brain become blocked or narrowed, leading to a reduction in blood flow to the affected area. It accounts for about 80% of all strokes. The brain cells and tissues begin to die within minutes from lack of oxygen and nutrients. Current treatments for ischemic stroke include pharmacological treatment with the tissue-type fibrinogen activator (r-tPA) and removal of blood clots by mechanical thrombectomy. However, these approaches have a low success rate and a limited window of efficacy. Therefore, there is an urgent need to develop new therapeutics for ischemic stroke.
Explore Our Expertise in Ischemic Stroke
At Ace Therapeutics, we provide comprehensive preclinical ischemic stroke research services to help clients develop breakthrough therapeutics. Our team of experts will guide you through the study design process, ensuring that scientific questions are addressed and the appropriate experimental model is used. We provide customized models of ischemic stroke, target discovery, and drug efficacy evaluation services to advance ischemic stroke research.
Custom Animal Models of Ischemic Stroke
Ace Therapeutics provides well-characterized stroke models, including animal models for focal ischemia (e.g., permanent and transient MCAO) and global ischemia (4VO). These models allow us to help our clients investigate the mechanisms of ischemic stroke, including blood-brain barrier (BBB) damage, cell death, and provide important data to support the development of drugs targeting neurodegeneration and neuroinflammation.
Custom In Vitro Models of Ischemic Stroke
We help our clients conduct a variety of studies in in vitro models of ischemic stroke, including:
- Studying the fundamental key control points and molecular pathways underlying necrotic cell death, programmed cell death, and autophagy in stroke.
- Performing high-throughput analysis to test novel potential neuroprotective drugs.
Types of Drugs We Can Develop for Ischemic Stroke
With our extensive experience and expertise in drug discovery, we can assist our clients in discovering new targets and developing novel therapies for ischemic stroke.
| Antiplatelet drugs | Thrombolytics | Anticoagulant drugs |
| Stem cell-based Therapies | Neuroprotective agents | Therapeutic antibodies |
Preclinical Evaluation of Ischemic Stroke Therapeutics
Ace Therapeutics offers comprehensive in vivo studies and endpoint assessments, delivering robust data to support critical research decisions in the evolving landscape of stroke drug development and biomedical research.
Behavioral Testing in Animal Models of Ischemic Stroke
Our team of neuroscientists uses a battery of standardized neurological and functional assessments to evaluate the effects of drugs on sensorimotor, cognitive, and emotional function in animal models of ischemic stroke. These assessments include, but are not limited to:
- Rotarod test
- Morris water maze
- Novel object recognition test
- Y-Maze test
- Open field test
Brain Imaging Services in Animal Models of Ischemic Stroke
Our laboratories are equipped with advanced imaging technologies, including high-resolution magnetic resonance imaging (MRI) and positron emission tomography (PET), which allow us to help clients accurately quantify the extent of brain damage, monitor disease progression, and track drug distribution in vivo.
Histological Evaluation of Ischemic Brain
Our team of scientists can prepare and stain brain slices upon request, utilizing histopathological techniques (such as TTC staining) and morphological analysis to assess ischemic brain lesions in animal models of ischemic stroke.
Assessment of Blood-Brain Barrier Disruption in Animal Models of Ischemic Stroke
We offer a range of techniques to assess BBB permeability and dysfunction in animal models of ischemic stroke. Our services enable clients to explore the mechanisms behind BBB disruption during stroke and to identify potential therapeutic targets for maintaining BBB integrity following ischemic events.
Through our expertise in the field of ischemic stroke, a wealth of animal models of stroke, and a dedicated drug development team, Ace Therapeutics is dedicated to advancing your research efforts in ischemic stroke and the development of innovative therapeutics. Our leading scientists support project design and project implementation in your study from concept to completion. Contact us today and embark on your path to discovery.
- Simats, A., et al. (2016). Neuroinflammatory biomarkers: from stroke diagnosis and prognosis to therapy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1862(3), 411-424.
